THEREFORE, clinical trial designers, investors, and regulators need to aim for more #clinicallyrelevant treatment target #endpoints beyond large magnitude wt loss, and also develop various drug #doses for the diverse intended populations and their different needs over time on their #weightmanagement journey
While this might seem empowering, a recent investigation revealed a disturbing lack of comprehensive care
Early research suggests GLP-1 receptor agonists may reduce migraine frequency in some people, possibly through effects on intracranial pressure
This study sought to determine whether these benefits extend to individuals with SLE, particularly those with lupus nephritis (LN), a population already vulnerable to cardiovascular disease and progressive kidney impairment
Consoli A, abal Berthoumieu S, Raffin M, Thuilleaux D, Poitou C, Coupaye M, et al